FUNGICIDAL COMPOSITIONS

Abstract

A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Claims

1. A fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) comprises a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof: ##STR00011## and component (B) is selected from the group consisting of respiration inhibitors: (B.1) inhibitors of complex III at Q.sub.o site selected from the group consiting of coumethoxystrobin, coumoxystrobin, dimoxystrobin, enoxastrobin, enestroburin, fenaminstrobin, fenoxystrobin/flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, trifloxystrobin, methyl (E)-2-[2-[(5-cyano-2-methyl-phenoxy)methyl]phenyl]-3-methoxy-prop-2-enoate, 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneaminooxymethyl)-phenyl)-2-methoxyimino-N-methyl-acetamide, (2E,3Z)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, (2E,3Z)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, pyribencarb, triclopyricarb/chlorodincarb, famoxadone, fenamidone, 1-[3-chloro-2-[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl]phenyl]-4-methyl-tetrazol-5-one, 1-[3-bromo-2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]phenyl]-4-methyl-tetrazol-5-one, metyltetraprole, 1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-fluoro-phenyl]-4-methyl-tetrazol-5-one, 1-[2-[[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxymethyl]-3-fluoro-phenyl]-4-methyl-tetrazol-5-one, 1-[2-[[4-(4-chlorophenyl)thiazol-2-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one, 1-[3-chloro-2-[[4-(p-tolyl)thiazol-2-yl]oxymethyl]phenyl]-4-methyl-tetrazol-5-one, 1-[3-cyclopropyl-2-[[2-methyl-4-(1-methyl pyrazol-3-yl)phenoxy]-methyl]phenyl]-4-methyl-tetrazol-5-one, 1-[3-(difluoromethoxy)-2-[[2-methyl-4-(1-methylpyrazol-3-yl)phenoxy]methyl]phenyl]-4-methyl-tetrazol-5-one, 1-methyl-4-[3-methyl-2-[[2-methyl-4-(1-methylpyrazol-3-yl)phenoxy]methyl]phenyl]tetrazol-5-one, 1-methyl-4-[3-methyl-2-[[1-[3-(trifluoromethyl)phenyl]-ethylideneamino]oxymethyl]phenyl]tetrazol-5-one, (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]-oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, pyriminostrobin and bifujunzhi; (B.2) inhibitors of complex III at Q.sub.i site selected from the group consisting of cyazofamid, amisulbrom, [(6S,7R,8R)-8-benzyl-3-[(3-hydroxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl]-2-methylpropanoate, fenpicoxamid, [(6S,7R,8R)-8-benzyl-3-[[4-methoxy-3-(propanoyloxymethoxy)pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl]-2-methylpropanoate, florylpicoxamid, [(1S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl] (2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propanoate and [(1S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propanoate; (B.3) inhibitors of complex II selected from the group consisting of benzovindiflupyr, bixafen, fluindapyr, boscalid, carboxin, pyraziflumid, fenfuram, cyclobutrifluram, fluopyram, flutolanil, fluxapyroxad, furametpyr, inpyrfluxam, isofetamid, isopyrazam, mepronil, oxycarboxin, penflufen, penthiopyrad, pydiflumetofen, N-[2-(3,4-difluorophenyl)phenyl]-3-(trifluoromethyl)pyrazine-2-carboxamide, sedaxane, pyrapropoyne, isoflucypram, tecloftalam, thifluzamide, 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3,5-trimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(difluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide, N-[(5-chloro-2-isopropyl-phenyl)methyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-pyrazole-4-carboxamide, 2-(difluoromethyl)-N-(1,1,3-trimethyl-indan-4-yl)yridine-3-carboxamide, 2-(difluoromethyl)-N-[(3R)-1,1,3-trimethylindan-4-yl]pyridine-3-carboxamide, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide, 2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide and 2-(difluoromethyl)-N-[(3R)-1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide; and (B.4) other respiration inhibitors selected from the group consisting of diflumetorim; tolfenpyrad; fenazaquin; nitrophenyl derivates: binapacryl, dinobuton, dinocap, fluazinam, meptyldinocap, ferimzone; organometal compounds: fentin salts, e. g. fentin-acetate, fentin chloride or fentin hydroxide; ametoctradin; and silthiofam.

2. The composition according to claim 1, wherein the weight ratio of (A) to (B) is from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, and even more preferably from 20:1 to 1:40.

3. The composition according to claim 1, wherein component (A) further comprises one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof: ##STR00012## wherein R.sup.1 is methyl or ethyl; each of X.sup.1, X.sup.2 and X.sup.3 is hydrogen, or X.sup.1, X.sup.2 and X.sup.3 are hydrogen, fluorine or hydroxyl, with the proviso that only one of X.sup.1, X.sup.2 and X.sup.3 is fluorine or hydroxyl; X.sup.4 is CH, S or hydroxymethylene; A.sup.3 is an α-amino acid residue selected from the group consisting of N-methyl-L-phenylalanine (L-MePhe), L-phenylalanine (L-Phe), β-hydroxy-N-methyl-L-phenylalanine (L-β-OH-MePhe), ortho-fluoro-N-methyl-L-phenylalanine (L-o-F-MePhe), meta-fluoro-N-methyl-L-phenylalanine (L-m-F-MePhe), para-fluoro-N-methyl-L-phenylalanine (L-p-F-MePhe), meta-bromo-N-methyl-L-phenylalanine (L-m-Br-MePhe), para-bromo-N-methyl-L-phenylalanine (L-p-Br-MePhe), meta-iodo-N-methyl-L-phenylalanine (L-m-I-MePhe), para-iodo-N-methyl-L-phenylalanine (L-p-I-MePhe), 3-phenyl-N-methyl-L-phenylalanine, 4-phenyl-N-methyl-L-phenylalanine, 3-(4-fluorophenyl)-N-methyl-L-phenylalanine, 4-(4-fluorophenyl)-N-methyl-L-phenylalanine, 3-(4-pyridinyl)-N-methyl-L-phenylalanine, 4-(4-pyridinyl)-N-methyl-L-phenylalanine, 3-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-4-pyridinyl)-N-methyl-L-phenylalanine, 3-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 3-[4-(piperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(piperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine,3-[4-(4-methylpiperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(4-methylpiperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine, β-oxo-N-methyl-L-phenylalanine (L-β-oxo-MePhe), β-acetoxy-N-methyl-L-phenylalanine (L-β-AcO-MePhe), N-methyl-L-tyrosine (L-MeTyr), O-methyl-N-methyl-L-tyrosine [L-MeTyr(Me)], N-methyl-L-alanine (L-MeAla), N-methyl-L-serine (L-MeSer), N-methyl-D-phenylalanine (D-MePhe), N-methyl-D-alanine (D-MeAla), N-methyl-D-valine (D-MeVal), N-methyl-D-serine (D-MeSer) and N-methyl-L-serine (L-MeSer) residues; A.sup.5 is an α-amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle), L-norvaline (L-Nva) and L-valine (L-Val) residues; A.sup.6 is an α-amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), N-methyl-L-allo-isoleucine (L-MeAlle) and L-valine (L-Val) residues; A.sup.7 is an α-amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and A.sup.8 is an α-amino acid residue selected from the group consisting of β-hydroxy-N-methyl-L-valine (L-β-OH-MeVal), γ-hydroxy-N-methyl-L-valine (L-γ-OH-MeVal), N-methyl-L-valine (L-MeVal), L-valine (L-Val), N-methyl-2,3-didehydro-L-valine (L-MeDH.sub.2,3Val), N-methyl-3,4-didehydro-L-valine (L-MeDH.sub.3,4Val), N-methyl-L-phenylalanine (L-MePhe), β-hydroxy-N-methyl-L-phenylalanine (L-β-OH-MePhe), N-methyl-L-threonine (L-MeThr), sarcosine (Sar) and N,β-dimethyl-L-aspartic acid (L-N,β-MeAsp) residues.

4. The composition according to claim 1, wherein component (A) further comprises at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G.

5. The composition according to claim 1, wherein component (A) comprises: from 10% to 99.9% by weight, preferably from 20% to 99.9% by weight, more preferably from 40% to 99.9% by weight of a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof, and from 0.1% to 90% by weight, preferably from 0.1% to 80% by weight, more preferably from 0.1% to 60% by weight of one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof.

6. The composition according to claim 1, wherein component (A) further comprises one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof: ##STR00013## wherein R.sup.1 is methyl or ethyl; X.sup.4 is CH, S or hydroxymethylene; A.sup.5 is an α-amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle) and L-valine (L-Val) residues; A.sup.6 is an α-amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), L-allo-isoleucine (L-Alle) and N-methyl-L-allo-isoleucine (L-MeAlle) residues; A.sup.7 is an α-amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and A.sup.8 is an α-amino acid residue selected from the group consisting of β-hydroxy-N-methyl-L-valine (L-β-OH-MeVal), γ-hydroxy-N-methyl-L-valine (L-γ-OH-MeVal), N-methyl-L-valine (L-MeVal), N-methyl-2,3-didehydro-L-valine (L-MeDH.sub.2,3Val), N-methyl-3,4-didehydro-L-valine (L-MeDH.sub.3,4Val), N-methyl-L-phenylalanine (L-MePhe), β-hydroxy-N-methyl-L-phenylalanine (L-β-OH-MePhe), N-methyl-L-threonine (L-MeThr), sarcosine (Sar) and N,β-dimethyl-L-aspartic acid (L-N,β-MeAsp) residues.

7. The composition according to claim 1, wherein component (B) is a compound selected from the group consisting of trifloxystrobin, pyraclostrobin, metyltetraprole, fluopyram, pydiflumetofen, isofetamid, fluxapyroxad, penthiopyrad, boscalid, cyclobutrifluram, fluazinam, florylpicoxamid, fenpicoxamid, isoflucypram, benzovindiflupyr, (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]-oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, [(1S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyly](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propanoate, [(1S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propanoate and 2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide.

8. The composition according to claim 1, further comprising an agriculturally acceptable carrier and/or formulation adjuvant, and optionally, a surfactant.

9. A method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition as defined in claim 1.

10. A method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) comprises Aureobasidin A and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, florylpicoxamid, fluopyram, pydiflumetofen, fluazinam, benzovindiflupyr, isoflucypram and metyltetrapole.

11. The method according to claim 9, wherein the component (A) is applied at a rate of from 10 g a.i./ha to 500 g a.i./ha in association with 25 g a.i./ha to 1000 g a.i./ha of component (B).

12. The method according to claim 9, wherein the phytophathogenic fungi are selected from the group consisting of Alternaria, Botrytis, Cercospora, Colletotrichum, Corynespora, Guignardia, Mycosphaerella, Monilinia, Penicillium, Phakopsora, Phomopsis, Podosphaera, Pseudopezicula, Septoria, Uncinula and Venturia.

13. The method according to claim 9, wherein the useful plant is selected from grains, fruits and tree nuts, vegetables, field crops, oil seed crops, forage crops, forest plants, horticulture crops, floriculture, greenhouse and nursery plants, propagative materials, culinary herbs and spices, and medicinal herbs.

14. The method according to claim 9, wherein said method controls or prevents phytophathogenic fungi selected from the group consisting of Alternaria, Cercospora, Colletotrichum, Corynespora, Mycosphaerella, Phakopsora, Phomopsis and Septoria on soybean plants.

15. Use of a composition comprising component (A) and component (B) as defined in claim 1 as a fungicide.

Description

BIOLOGICAL EXAMPLES

[0254] The compositions according to the invention are tested for their biological (fungicidal) activity using application rates wherein the component (A) is applied at a rate of from 10 g a.i./ha to 500 g a.i./ha in association with 25 g a.i./ha to 1000 g a.i./ha of component (B).

[0255] The compositions according to the invention are tested for their biological (fungicidal) activity as dimethylsulfoxide (DMSO) solutions using one or more of the following protocols (Examples 1-1 and 1-2). A standard description of the liquid culture tests is provided in Example 1.

[0256] Aureobasidin A and its synthesis are known from Takesako et al., The Journal of Antibiotics, 1991, 44, 919-924. Aureobasidin A is separated from the fermentation broth by extraction with ethyl acetate, followed by extraction of the ethyl acetate concentrate with a mixture of MeOH:H.sub.2O (80% by volume) and cyclohexane (20% by volume), and purified by silica gel column chromatography (silica-gel, elution with hexane:ethyl acetate) followed by reverse phase column chromatography (RP18, elution with acetonitrile:H20). As already indicated, components (B) of the compositions are known and are commercially available and/or can be prepared using procedures known in the art and/or procedures reported in the literature.

Example 1

Liquid Culture Tests in Well Plates

[0257] Mycelia fragments or conidia suspensions of a fungus, prepared either freshly from liquid cultures of the fungus or from cryogenic storage, are directly mixed into nutrient broth. DMSO solutions of the test compound (max. 10 mg/mL) is diluted with 0.025% Tween20 by factor 50 and 10 μL of this solution is pipetted into a microtiter plate (96-well format). The nutrient broth containing the fungal spores/mycelia fragments is then added to give an end concentration of the tested compound. The test plates are incubated in the dark at 24° C. and 96% relative humidity (rh). The inhibition of fungal growth is determined photometrically and visually after 3-7 days, depending on the pathosystem, and percent antifungal activity relative to the untreated check is calculated.

Example 1-1

Botrytis cinerea (Gray Mould)

[0258] Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of the test compositions into a microtiter plate (96-well format), the nutrient broth containing the fungal spores was added. The test plates were incubated at 24° C. and the inhibition of growth was determined photometrically after 72 hours.

Example 1-2

Alternaria solani (Early Blight of Tomato/Potato)

[0259] Conidia of the fungus from cryogenic storage were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a DMSO solution of the test compositions into a microtiter plate (96-well format) the nutrient broth containing the fungal spores was added. The test plates were incubated at 24° C. and the inhibition of growth was determined photometrically after 48 hours.

[0260] Results

[0261] Results from the tests outlined above are shown below in Tables 1 to 17. These data show that synergistic fungicidal activity is observed for the combination of Aureobasidin A and another active ingredient of component (B) against Botrytis cinerea and Alternaria solani at certain weight ratios. According to COLBY, in mathematical terms the synergism factor SF corresponds to O/E. In the agricultural practice an SF of ≥1.1 indicates significant improvement over the purely complementary addition of activities (expected activity), while an SF of 0.9 in the practical application routine signals a loss of activity compared to the expected activity.

TABLE-US-00003 TABLE 1 Fungicidal activity of a composition of Aureobasidin A and azoxystrobin against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Azoxystrobin Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0003 0 0.0025 2 0.0050 24 0.0100 23 0.0313 31 0.0625 46 0.1250 61 0.0003 0.0625 1:200  46 55 0.0025 0.0313 1:12.5 33 51 0.0025 0.0625 1:25   47 56 0.0050 0.0625 1:12.5 59 69 0.0100 0.1250 1:12.5 70 78

TABLE-US-00004 TABLE 2 Fungicidal activity of a composition of Aureobasidin A and azoxystrobin against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Azoxystrobin Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0001 8 0.0002 2 0.0003 0 0.0006 9 0.0012 0 0.0025 2 0.0078 30 0.0156 60 0.0313 72 0.0001 0.0078 1:100  35 45 0.0001 0.0156 1:200  63 71 0.0002 0.0078 1:50   31 45 0.0003 0.0078 1:25   30 45 0.0006 0.0078 1:12.5 36 52 0.0012 0.0156 1:12.5 60 75 0.0025 0.0313 1:12.5 72 81

TABLE-US-00005 TABLE 3 Fungicidal activity of a composition of Aureobasidin A and trifloxystrobin against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Trifloxystrobin Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0001 2 0.0006 6 0.0025 1 0.0078 44 0.0313 71 0.0001 0.0078 1:100  44 53 0.0006 0.0078 1:12.5 47 55 0.0006 0.0313 1:50   73 81 0.0025 0.0313 1:12.5 71 78

TABLE-US-00006 TABLE 4 Fungicidal activity of a composition of Aureobasidin A and florylpicoxamid against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Florylpicoxamid Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0003 3 0.0012 0 0.0025 11 0.0050 17 0.0100 17 0.0200 38 0.0313 41 0.0625 56 0.1250 59 0.0003 0.0313  1:100 43 47 0.0012 0.0313 1:25  41 47 0.0012 0.1250  1:100 59 67 0.0025 0.0313  1:12.5 47 55 0.0050 0.0313 1:6.2 51 66 0.0100 0.0625 1:6.2 64 75 0.0100 0.1250  1:12.5 66 75 0.0200 0.1250 1:6.2 75 86

TABLE-US-00007 TABLE 5 Fungicidal activity of a composition of Aureobasidin A and florylpicoxamid against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Florylpicoxamid Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0003 0 0.0313 53 0.0003 0.0313 1:100 53 59

TABLE-US-00008 TABLE 6 Fungicidal activity of a composition of Aureobasidin A and fluopyram against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Fluopyram Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0100 25 0.1250 42 0.0100 0.1250 1:12.5 56 67

TABLE-US-00009 TABLE 7 Fungicidal activity of a composition of Aureobasidin A and fluopyram against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Fluopyram Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0006 0 0.0012 0 0.0025 0 0.0313 49 0.0625 63 0.0006 0.0313 1:50 49 56 0.0012 0.0313 1:25 49 55 0.0012 0.0625 1:50 63 69 0.0025 0.0313 .sup. 1:12.5 49 62

TABLE-US-00010 TABLE 8 Fungicidal activity of a composition of Aureobasidin A and pydiflumetofen against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Pydiflumetofen Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0002 0 0.0003 0 0.0012 7 0.0025 15 0.0050 17 0.0016 27 0.0031 41 0.0063 51 0.0002 0.0031 1:20  41 46 0.0003 0.0031 1:10  41 47 0.0012 0.0016 1:1.2 32 44 0.0025 0.0031 1:1.2 50 55 0.0050 0.0063 1:1.2 60 67

TABLE-US-00011 TABLE 9 Fungicidal activity of a composition of Aureobasidin A and pydiflumetofen against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Pydiflumetofen Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0001 8 0.0003 0 0.0006 0 0.0012 0 0.0008 28 0.0016 52 0.0031 71 0.0001 0.0008 1:10  34 41 0.0001 0.0016 1:20  56 64 0.0003 0.0016 1:5.sup.  52 57 0.0006 0.0008 1:1.2 28 41 0.0006 0.0016 1:2.5 52 59 0.0012 0.0031 1:2.5 71 80

TABLE-US-00012 TABLE 10 Fungicidal activity of a composition of Aureobasidin A and fluazinam against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Fluazinam Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.005 24 0.010 24 0.020 50 0.040 85 0.0006 3 0.0012 6 0.0025 8 0.0050 6 0.0100 8 0.005 0.0050 1:1 28 52 0.010 0.0060 16:1  26 43 0.010 0.0012 8:1 28 43 0.010 0.0050 2:1 28 81 0.010 0.0100 1:1 30 97 0.020 0.0012 16 :1.sup.  53 76 0.020 0.0025 8:1 54 89 0.020 0.0050 4:1 53 96 0.020 0.0100 2:1 54 98 0.040 0.0025 16:1  86 99 0.040 0.0050 8:1 86 98 0.040 0.0100 4:1 86 99

TABLE-US-00013 TABLE 11 Fungicidal activity of a composition of Aureobasidin A and fluazinam against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Fluazinam Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.005 12 0.040 46 0.0003 11 0.0025 11 0.0050 11 0.005 0.0003 1:100 22 46 0.040 0.0025 1:100 51 63 0.040 0.0050 1:100 51 58

TABLE-US-00014 TABLE 12 Fungicidal activity of a composition of Aureobasidin A and benzovindiflupyr against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Benzovindiflupyr Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0006 0 0.0012 8 0.0025 8 0.0050 4 0.0200 33 0.0031 26 0.0063 37 0.0250 57 0.0006 0.0031 1:5.sup.  26 41 0.0012 0.0063 1:5.sup.  42 47 0.0025 0.0031 1:1.2 32 45 0.0050 0.0063 1:1.2 40 60 0.0050 0.0250 1:5.sup.  59 73 0.0200 0.0250 1:1.2 71 79

TABLE-US-00015 TABLE 13 Fungicidal activity of a composition of Aureobasidin A and benzovindiflupyr against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Benzovindiflupyr Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0100 0 0.0125 52 0.0100 0.0125 1:1.2 52 63

TABLE-US-00016 TABLE 14 Fungicidal activity of a composition of Aureobasidin A and isoflucypram against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Isoflucypram Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0006 0 0.0012 0 0.0031 37 0.0063 50 0.0006 0.0031 1:5 37 45 0.0012 0.0063 1:5 50 63

TABLE-US-00017 TABLE 15 Fungicidal activity of a composition of Aureobasidin A and isoflucypram against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Isoflucypram Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0003 3 0.0016 22 0.0003 0.0016 1:5 24 40

TABLE-US-00018 TABLE 16 Fungicidal activity of a composition of Aureobasidin A and metyltetrapole against Botrytis cinerea as described in Example 1-1 above. Expected (additive) Combined Aureobasidin A Metyltetrapole Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0003 3 0.0025 10 0.0050 8 0.0125 43 0.0250 56 0.0003 0.0250  1:80 58 66 0.0025 0.0125 1:5 49 56 0.0050 0.0250 1:5 60 69

TABLE-US-00019 TABLE 17 Fungicidal activity of a composition of Aureobasidin A and metyltetrapole against Alternaria solani as described in Example 1-2 above. Expected (additive) Combined Aureobasidin A Metyltetrapole Ratio (A) (B) activity inhibition (A) (B) compound inhibition inhibition (Colby) (observed) (ppm) (ppm) (A):(B) (%) (%) (%) (%) 0.0001 0 0.0002 0 0.0006 0 0.0012 0 0.0025 0 0.0062 38 0.0125 73 0.0001 0.0062 1:80 38 55 0.0002 0.0062 1:40 38 53 0.0006 0.0062 1:10 38 48 0.0012 0.0062 1:5  38 49 0.0025 0.0125 1:5  73 82